KRAS and colorectal carcinoma: While targeting of KRAS c.35 G > T reduced the viability of SW620 and SW480 cells to 50–70% in the absence of puromycin, antibiotic selection resulted in a further reduction of CRC cell viability to below 5% (Fig. 1c, Supplementary Fig. 4).